222 related articles for article (PubMed ID: 27091555)
1. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.
Carrion AF; Martin P
Expert Opin Drug Saf; 2016 Jun; 15(6):883-90. PubMed ID: 27091555
[TBL] [Abstract][Full Text] [Related]
2. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
El Kassas M; Elbaz T; Abd El Latif Y; Esmat G
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1413-1421. PubMed ID: 27603877
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
[TBL] [Abstract][Full Text] [Related]
4. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
Al-Salama ZT; Deeks ED
Drugs; 2017 May; 77(8):911-921. PubMed ID: 28417245
[TBL] [Abstract][Full Text] [Related]
5. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui LR; Mansour H; Chahine EB
Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.
Ahmed H; Abushouk AI; Menshawy A; Attia A; Mohamed A; Negida A; Abdel-Daim MM
Ann Hepatol; 2018; 17(1):18-32. PubMed ID: 29311409
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
Suda G; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Hasebe C; Abe M; Haga H; Ueno Y; Masakane I; Abe K; Takahashi A; Ohira H; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Kawakami A; Kumagai K; Terasita K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
J Gastroenterol; 2019 Jan; 54(1):78-86. PubMed ID: 30019127
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
[TBL] [Abstract][Full Text] [Related]
12. Elbasvir and grazoprevir for the treatment of hepatitis C.
Wang SJ; Huang CF; Yu ML
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
[No Abstract] [Full Text] [Related]
13. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
14. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
Alric L; Bonnet D
Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.
Atsukawa M; Tsubota A; Toyoda H; Takaguchi K; Kondo C; Okubo T; Hiraoka A; Michitaka K; Fujioka S; Uojima H; Watanabe T; Ikeda H; Asano T; Ishikawa T; Matsumoto Y; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Mikami S; Tanaka Y; Kumada T; Iwakiri K
J Gastroenterol Hepatol; 2019 Feb; 34(2):364-369. PubMed ID: 30144366
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
Morikawa K; Nakamura A; Shimazaki T; Sakamoto N
Drug Des Devel Ther; 2018; 12():2749-2756. PubMed ID: 30233138
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
[TBL] [Abstract][Full Text] [Related]
18. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
[TBL] [Abstract][Full Text] [Related]
19. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
Suraweera D; Weeratunga AN; Saab S
Drug Des Devel Ther; 2016; 10():2119-27. PubMed ID: 27418810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
